Doses studied
Ipamorelin dosage, exactly as the literature recorded it
The doses administered in published studies — by species, route and duration — with no number ever offered as a human protocol.
Read this first
This page reports the ipamorelin dosage figures that appear in published studies, and nothing more. Every number below was administered to a specific species, by a specific route, in a specific experiment — it is a record of what researchers did, not a suggestion for what anyone should do. There is no approved human dose of ipamorelin, because it was never approved. The community protocols that pair it with CJC-1295 and quote microgram amounts have no controlled-trial basis in humans, and this digest will not invent one. What the literature can tell you cleanly is the half-life (how fast it clears), the routes that have been studied, and the doses used in the handful of real experiments. We give you those, in third person, with citations — and we leave the decision-making where it belongs, outside a research digest.
Doses recorded in the studies
In the human pharmacokinetic study, healthy men received single intravenous infusions of 4.21 to 140.45 nmol/kg over fifteen minutes [2]. In the human Phase 2 ileus trial, patients received 0.03 mg/kg intravenously twice daily for up to seven days [3]. In the rat bone-growth study, animals received 18, 90 or 450 micrograms per day subcutaneously, split three times daily, for fifteen days [4]. In the 2024 ferret cachexia study, ipamorelin was given at 1 to 3 mg/kg intraperitoneally [5]. These span vastly different species and goals; none translates to a human regimen, and the contrast between a microgram-per-day rat protocol and a milligram-per-kilogram ferret dose is itself a caution against casual extrapolation.
Half-life and pharmacokinetics
Ipamorelin's terminal half-life in healthy human volunteers is approximately two hours after intravenous dosing, with clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg [2]. The growth-hormone response it produces is a single discrete pulse peaking around forty minutes (0.67 h) after dosing, then subsiding [2]. The kinetics were dose-proportional across the tested range, meaning the body handled larger doses in a linear, predictable way [2]. This short half-life and single-pulse profile is exactly the pharmacology that the combination protocols try to lengthen by adding a long-acting GHRH analog.
How much cjc-1295 ipamorelin should i take
The honest answer to "how much cjc-1295 ipamorelin should i take" is that no published controlled trial establishes a human dose for the combination, so this digest does not provide one. The CJC-1295 human data that exist describe 30 to 60 micrograms per kilogram subcutaneously producing dose-dependent growth-hormone increases [11], but that is single-agent CJC-1295 pharmacology in a study, not a combination protocol and not a recommendation. Ipamorelin's own human exposure was characterized only intravenously [2][3]. The subcutaneous, paired, repeated-dose regimens circulated in communities are anecdotal and untested as a combination — described here as protocols people use, never as protocols this site endorses.
How to reconstitute cjc-1295 ipamorelin 5mg
On "how to reconstitute cjc-1295 ipamorelin 5mg": ipamorelin is supplied as a lyophilized (freeze-dried) powder, as free base or acetate salt, and is reconstituted with bacteriostatic water for research handling [2]. As a peptide it degrades with heat and repeated freeze-thaw cycles, so reconstituted solution is generally kept refrigerated. These are general peptide-handling observations drawn from the research-supply literature, not a clinical preparation instruction, and this digest gives no step-by-step mixing protocol or injection guidance — that falls outside an editorial summary of the science.
Routes that have been studied
Ipamorelin has been studied intravenously (human pharmacokinetics and the clinical trial; rodent efficacy), subcutaneously (the rodent bone and body-composition studies, and the dominant route in community use), intraperitoneally (rodent and ferret efficacy work), and intranasally (rodent pharmacokinetics, with roughly 20 percent bioavailability) [2][4][5]. Oral dosing applies only to engineered ipamorelin-derived analogs, not to ipamorelin itself, which is not orally bioavailable [4]. The mismatch between the routes that were actually studied and the route most people use is one more reason the human safety picture is genuinely incomplete.
Why study doses do not translate to a protocol
It is tempting to read a study dose as a recipe, and it is a mistake. The human numbers come from intravenous infusions in a controlled setting — a 1999 pharmacokinetic study using doses up to 140.45 nmol/kg [2], and a clinical trial using 0.03 mg/kg twice daily for at most a week [3]. The animal numbers are scaled to the metabolism of rats and ferrets, not people, and even within the animal work the units jump from micrograms per day in a rat skeleton study [4] to milligrams per kilogram in a ferret cachexia study [5]. None of these establishes how a subcutaneously self-administered dose would behave in a person over weeks or months, because no study has measured that. A dose that produced a single growth-hormone pulse on an infusion pump tells you about pharmacology, not about a safe or effective regimen.
Stability, handling and anti-doping detection
As supplied, ipamorelin is a lyophilized powder kept dry and cold; once reconstituted it is treated like any peptide — refrigerated, shielded from heat and from repeated freeze-thaw, which degrade it [2]. These are general research-supply handling notes, not preparation instructions. One further fact belongs on any honest dosage page: ipamorelin is a growth-hormone secretagogue prohibited in sport at all times under the WADA list (category S2), and its class is detectable in urine by accredited anti-doping laboratories. Anyone subject to drug testing should treat the compound as detectable, regardless of dose or route.